Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Marita Paassilta a Department of Internal Medicine and
Biocenter Oulu, University of Oulu, Kajaanintie 50, FIN-90220 Oulu,
Finland, b National Public
Health Institute, Mannerheimintie 166, FIN-00300, Helsinki, Finland
Correspondence to: Professor Kesäniemi
antero.kesaniemi{at}oulu.fi
Light or moderate alcohol consumption decreases the risk of
coronary heart disease.1 Beneficial changes in high
density lipoprotein cholesterol concentrations are, however, observed at quite high levels of alcohol consumption We performed a population based cross sectional study of 300 men
aged 40-60 years selected randomly by age stratification; 259 (86%)
participated in the study. Subjects were divided into four groups by
alcohol consumption: abstainers (mostly lifetime teetotallers; 37 men)
and three groups of drinkers. Drinkers in the lowest third consumed
<39 g alcohol/week (74 men), those in the middle third 39-132 g/week
(75), and those in the highest third >132 g/week (73). Alcohol intake
was ascertained from a questionnaire on the amount and quality of
alcoholic beverages consumed during the previous two weeks. Plasma
Lp(a) lipoprotein concentrations were determined by a two site
immunoradiometric assay that showed a close correlation with two
different enzyme linked immunoassays (r
that is,
20 units per
week, 1 unit being 10-12 g.2 Therefore, other factors may be responsible for decreasing the risk of coronary heart disease when
alcohol is consumed in social amounts. We studied the relation between
light and moderate alcohol intake and Lp(a) lipoprotein concentrations.
Lp(a) lipoprotein is an independent risk factor for coronary heart
disease3 and is affected by alcohol misuse.4
![]()
Subjects, methods, and results
0.96).
Liver function was assessed by measuring lipid and enzyme
concentrations in fasting blood samples using standard techniques.
Statistical analysis was carried out with the SAS software
package. The groups were similar for age and smoking habits. The body
mass index, waist to hip ratio, systolic and diastolic blood pressure,
and alanine aminotransferase values were highest in subjects in the
third drinking >132 g/week compared with those in the two lower
thirds and with non-drinkers (P<0.001 for each parameter, analysis of
variance). The mean concentrations of serum
-glutamyltransferase
increased with increasing alcohol intake
that is, 34, 33, 49, and
64 U/l respectively for teetotallers, and the lowest, middle, and
highest third of drinkers (P<0.001). Blood glucose and serum insulin
values did not differ between the groups. Lp(a) lipoprotein
concentrations were higher (median, 206 mg/l) in the teetotallers than
in the drinkers. Lp(a) lipoprotein concentrations for the lowest,
middle, and highest alcohol thirds were 137, 109, and 94 mg/l
(P<0.05, Kruskal-Wallis test) (figure). As noted in other white
populations, we observed a highly skewed distribution of Lp(a)
lipoprotein concentrations and a wide range within the population. The
ranges were similar in the study groups (figure). Lp(a) lipoprotein
concentrations showed a weak but significant correlation with body mass
index, waist to hip ratio, and insulin concentrations (Pearson's
correlation coefficients
0.15,
0.14, and
0.15 respectively,
P<0.025 for each correlation). There were no significant differences
in high density lipoprotein (means for the teetotallers, and the
lowest, middle, and highest thirds of alcohol consumption 1.19, 1.19, 1.23, and 1.27 mmol/l respectively) or low density lipoprotein
cholesterol concentrations between the groups.

View larger version (18K):
[in a new window]
Plasma Lp(a) lipoprotein concentrations in four study groups.
Boxes represent median and middle quarters of Lp(a) lipoprotein
concentration and whiskers represent lowest and highest quarters
| |
Comment |
|---|
Our report shows that social drinking
that is, <39 g
alcohol/week or 1-4 units/week
is associated with low Lp(a)
lipoprotein concentrations in middle aged men. No changes were observed
in high density lipoprotein cholesterol or low density lipoprotein cholesterol concentrations, blood pressure, or liver enzyme
concentrations.
Other studies of alcohol consumption and Lp(a) lipoprotein cholesterol
concentrations have dealt with differences between men and women,
analysed alcohol intake qualitatively,5 and compared
heterogeneous groups
that is, non-drinkers together with those who
drink regularly on three or less days a week. To our knowledge, ours is
the first study to show a relation between moderate alcohol consumption
and Lp(a) lipoprotein concentrations. We conclude that low Lp(a)
lipoprotein concentrations may be one factor explaining low mortality
and retarded progression of coronary artery disease in social drinkers.
| |
Acknowledgments |
|---|
We thank Ms Saija Kortetjärvi, Ms Anna-Riitta Malinen, and Ms Liisa Laine for technical and secretarial support, and Markku Linnaluoto for help with the statistics.
Contributors: MP participated in data analysis, writing the paper, and a discussion of the core ideas. KK discussed the study hypothesis and core ideas, and participated in data analysis and writing the paper. AOR participated in the study design, patient investigations, and data collection. MJS discussed the study hypothesis and core ideas, and participated in writing the paper. ML participated in the study design, data collection, and writing the paper. AR participated in the study design, statistical analysis, and writing the paper. YAK was the principal investigator; he initiated and coordinated the formulation of the primary study hypothesis, designed the protocol, discussed core ideas, and participated in data interpretation and writing the paper. YAK will act as guarantor of the study.
Funding: This study was supported by grants from the Finnish Foundation for Alcohol Studies, the Finnish Foundation for Cardiovascular Research, and the Medical Council of the Academy of Finland.
Conflict of interest: None.
| |
References |
|---|
|
|
|---|
(Accepted 24 June 1997)